<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The AIO KRK-0306 trial compares the efficacy of infusional <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>, folinic acid, irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in first-line treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) </plain></SENT>
<SENT sid="1" pm="."><plain>In October 2008, an amendment terminated the inclusion of patients with KRAS-mutated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>This subgroup of patients is evaluated in the present analysis, while the study is ongoing for patients with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Patients were randomly assigned to FOLFIRI (Tournigand regimen) every 2 weeks plus cetuximab (400 mg/m2 day 1, followed by 250 mg/m2 weekly=arm A) or bevacizumab (5 mg/kg every 2 weeks=arm B) </plain></SENT>
<SENT sid="4" pm="."><plain>Among 336 randomised patients, KRAS mutation was demonstrated in 100 assessable patients </plain></SENT>
<SENT sid="5" pm="."><plain>The primary study end point was objective response rate (ORR) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: ORR was 44% [95% confidence interval (CI) 29% to 59%] in arm A versus 48% (95% CI, 33% to 62%) in arm B </plain></SENT>
<SENT sid="7" pm="."><plain>Progression-free survival was 7.5 versus 8.9 months (hazard ratio: 1.0) and overall survival was 22.7 versus 18.7 months (hazard ratio: 0.86) in arms A versus B, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: This is the first head to head comparison of cetuximab versus bevacizumab in first-line treatment of mCRC </plain></SENT>
<SENT sid="9" pm="."><plain>In the present evaluation of patients with KRAS-mutated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e>, neither strategy demonstrated a clearly superior outcome </plain></SENT>
</text></document>